整理 | GLP1减重宝典内容团队几年前,一组科学家在分析丹麦的健康登记数据时发现了一个引人注目的现象:使用诺和诺德A/S上一代糖尿病药物Victoza(或类似的GLP-1类药物)治疗的糖尿病患者,患上痴呆症的比例明显低于采用其他治疗方式的患者。具体来说,连续使用该GLP-1药物两年以上的成年人,患痴呆症的风险大约降低了20%。“这本身并不能作为确凿证据,”诺和诺德首席科学官马丁·霍尔斯特·兰格(...
Source Link整理 | GLP1减重宝典内容团队几年前,一组科学家在分析丹麦的健康登记数据时发现了一个引人注目的现象:使用诺和诺德A/S上一代糖尿病药物Victoza(或类似的GLP-1类药物)治疗的糖尿病患者,患上痴呆症的比例明显低于采用其他治疗方式的患者。具体来说,连续使用该GLP-1药物两年以上的成年人,患痴呆症的风险大约降低了20%。“这本身并不能作为确凿证据,”诺和诺德首席科学官马丁·霍尔斯特·兰格(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.